2025-2030年全球神經退化性疾病新治療方法市場

Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030

出版日期: 2025年08月19日 | 出版商:

Frost & Sullivan | 英文 39 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

推動神經系統疾病未來的創新策略

本報告對包括阿茲海默症和帕金森氏症在內的神經退化性疾病治療的現狀和未來進行了全面檢驗，強調了關鍵的成長動力（如精準醫療、診斷的人工智慧範式以及老齡化的變革大趨勢）及其面臨的障礙（如競爭性質和地緣政治動盪）。

本報告探討了新興治療方法，包括生物製藥（單株抗體、核酸療法）、小分子藥物（澱粉樣變性抑制劑、NMDA 拮抗劑）以及替代療法（臨床營養保健品、微生物組）。報告也檢驗了融合與顛覆等重要策略，以及來自知名學術機構和產業相關人員的關鍵新藥和新設備的研發管線回顧。報告還重點分析了疾病修正治療、免疫療法藥物和精準醫療領域的高成長機會，以及融資趨勢和與策略夥伴的合作。

本研究整合了技術、臨床和市場趨勢，為相關人員提供可行的建議，並強調新興神經退化治療領域數兆美元的高成長機會。

神經退化性疾病的事實與挑戰
了解與老齡化相關的最普遍、影響最深遠的腦部疾病
阿茲海默症和帕金森氏症是主要的神經退化性疾病
神經退化性疾病的新型生物製藥治療方法
機轉與臨床應用：核酸治療
單株抗體的作用機轉及臨床應用
微生物治療的機轉及臨床應用
神經退化性疾病的新型小分子治療方法
澱粉樣變性抑制劑的作用機轉及臨床應用
NMDA受體拮抗劑的作用機轉及臨床應用
膽鹼酯酶抑制劑的作用機轉及臨床應用
神經退化性疾病的替代療法
膳食補充劑的作用機轉及臨床應用
機制與臨床應用：阿育吠陀與傳統醫學

創新前景：阿茲海默症和帕金森氏症臨床管線概述

阿茲海默症臨床管線概述
臨床研發管線創新者簡介
帕金森氏症臨床管線概述
臨床研發管線創新者簡介

資金籌措、夥伴關係與收購

資金籌措分析
重要夥伴關係與收購

前景

創新生物遞送系統的前景
特異性單株抗體的前景
基因治療與基因工程的觀點

神經退化性疾病領域的成長機會

成長機會1：精準醫療與個人化治療的進步
成長機會2：疾病修正治療的突破
成長機會3：免疫治療方法的進展

後續步驟

成長機會的益處和影響
後續步驟
免責聲明

簡介目錄

Product Code: DB2D

Innovative Strategies Driving the Future of Neuro Diseases

This report is a thorough examination of the current and future face of therapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's. It articulates important growth drivers (e.g., precision medicine, AI paradigm for diagnostics, and the transformational megatrends of aging populations) and barriers they will face (e.g., the nature of competition and geopolitical upheaval).

The report will examine emerging therapeutic modalities including biologics (monoclonal antibodies and nucleic acid therapies), small molecules (amyloidogenesis inhibitors and NMDA antagonists), and alternative therapies (clinical nutraceuticals and microbiome). It also examines essential strategies such as convergence and disruption, as well as pipeline reviews of major emerging drugs and devices from prominent academic and industry participants. It pinpoints high-growth opportunities, such as disease-modifying therapies, immunotherapy drug products, and precision medicine along with funding trends and collaborations with strategic partners.

The study integrates technological, clinical, and market trends to provide actionable recommendations to stakeholders and emphasize the high-growth, multitrillion-dollar opportunities in the emerging neurodegenerative therapeutics space.

Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on Emerging Therapeutics for Neurodegenerative Diseases
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints

Emerging Therapies to Address Neurodegenerative Diseases

Neurodegenerative Diseases: Facts and Challenges
Understanding the Most Prevalent and Impactful Disorders of the Aging Brain
Alzheimer's and Parkinson's Diseases Are the Leading Neurodegenerative Disorders
Neurodegenerative Diseases: Emerging Therapies Under Biologics
Mechanism and Clinical Applications: Nucleic Acid Therapies
Mechanism and Clinical Applications: Monoclonal Antibodies
Mechanism and Clinical Applications: Microbiome-Based Therapies
Neurodegenerative Diseases: Emerging Therapies Under Small Molecules
Mechanism and Clinical Applications: Amyloidogenesis Inhibitors
Mechanism and Clinical Applications: NMDA Receptor Antagonist
Mechanism and Clinical Applications: Cholinesterase Inhibitors
Neurodegenerative Diseases: Alternative Therapies
Mechanism and Clinical Applications: Nutraceuticals
Mechanism and Clinical Applications: Ayurvedic and Traditional Practices

Innovation Landscape: Clinical Pipeline Overview For Alzheimer's and Parkinson's Disease

Clinical Pipeline Overview for Alzheimer's
Clinical Pipeline Innovator Profiles
Clinical Pipeline Overview for Parkinson's
Clinical Pipeline Innovator Profiles

Funding, Partnerships, and Acquisitions

Funding Analysis
Key Partnerships and Acquisitions

Outlook

Innovative Biologic Delivery Systems Outlook
Target-Specific Monoclonal Antibodies Outlook
Gene Therapy and Genetic Engineering Outlook

Growth Opportunity Universe For Neurodegenerative Diseases

Growth Opportunity 1: Advancements in Precision Medicine and Personalized Therapies
Growth Opportunity 2: Breakthroughs in Disease-Modifying Therapies
Growth Opportunity 3: Advancing Immunotherapeutic Approaches